Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8658198 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
Dec, 2027
(3 years from now) | |
US8470361 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
May, 2030
(6 years from now) | |
US11020388 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
US11020387 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
US10946010 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
US8940330 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
US9439900 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
US9259421 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
US10874661 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
US11433066 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) |
Zubsolv is owned by Orexo Us Inc.
Zubsolv contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Zubsolv has a total of 10 drug patents out of which 0 drug patents have expired.
Zubsolv was authorised for market use on 03 July, 2013.
Zubsolv is available in tablet;sublingual dosage forms.
Zubsolv can be used as sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone, sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone, use of zubsolv for treatment of opioid dependence.
The generics of Zubsolv are possible to be released after 18 September, 2032.
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 July, 2013
Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxo...
Dosage: TABLET;SUBLINGUAL